
Oncology NEWS International
- Oncology NEWS International Vol 15 No 6
- Volume 15
- Issue 6
Phase I Trial of NPI-0052 Begins
Nereus Pharmaceuticals, Inc. has initiated a phase I trial of its novel, small molecule proteasome inhibitor, NPI-0052, in patients with solid tumors and lymphomas. The trial will enroll approximately 50 patients at two sites, M.D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center. NPI-0052 was discovered during the fermentation of Salinispora sp, a new class of Gram-positive marine bacteria, Nereus said in a press release.
SAN DIEGO, CalifNereus Pharmaceuticals, Inc. has initiated a phase I trial of its novel, small molecule proteasome inhibitor, NPI-0052, in patients with solid tumors and lymphomas. The trial will enroll approximately 50 patients at two sites, M.D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center. NPI-0052 was discovered during the fermentation of Salinispora sp, a new class of Gram-positive marine bacteria, Nereus said in a press release.
Articles in this issue
almost 20 years ago
Triple-Negative Cancers More Common in Young Black Ptsalmost 20 years ago
Artists Turn Flowers & Curves Into 'Forms' and 'Figures'almost 20 years ago
Study to Examine Outcomes Disparities in Pediatric ALLalmost 20 years ago
Thalidomide Has 'Changed the Paradigm' in Myeloma Rxalmost 20 years ago
CA4P Gets Orphan Drug Statusalmost 20 years ago
Testicular Ca Survivors at Increased Risk for CV Eventsalmost 20 years ago
A Novel Brings a Cancer Research Laboratory to Lifealmost 20 years ago
NCCN Reveals New Venous Thromboembolism Guidelinealmost 20 years ago
Lapatinib New Option for Metastatic HER2+ Breast Caalmost 20 years ago
FDA Approves Dacogen for Treating All MDS SubtypesNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.






















































